



Please be informed of a recent update to the product information for Zaponex 25 and 100 mg tablets which has been approved by MHRA on 17 June 2020. In line with these changes, we expect approval of a similar update to Zaponex ODT formulations shortly.

With the latest changes, the Zaponex Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL) have been harmonised with the safety information contained in the Clozaril (clozapine) product information.

The updated patient information leaflet (PIL) will be included in the packaging of our product as soon as possible.

Please note that new product information for all the Zaponex strengths is (tablets), or will shortly be (ODT formulations), available via the ZTAS website, as well as via the electronic Medicines Compendium (eMC) website.

We trust that you find this information useful,  
Yours sincerely,

**Leyden Delta BV**  
Zaponex Treatment Access System

**Most important changes:**

**Zaponex SUMMARY OF PRODUCT CHARACTERISTICS (SPC):**

- **Section 1. UK Zaponex® Official Recommendations:** addition of paragraph 'Advice on monitoring of clozapine blood levels' for certain clinical situations, such as when a patient ceases smoking or switches to e-cigarettes, when concomitant medicines may interact to increase clozapine blood levels, where poor clozapine metabolism is suspected, when a patient has pneumonia or other serious infection and in the event of onset of symptoms suggestive of toxicity.
- **Section 4.8 undesirable effects:** Several new adverse reactions derived from post-marketing experience (spontaneous case reports and literature) have been included in the tabulated list of adverse reactions (table 4). These reactions, as included in the below mentioned sections, have all been ranked under the frequency estimate category "not known" because the frequency cannot be estimated from the available data. Additionally, one specification was made to the adverse reaction in category Renal and Urinary disorders frequency category 'very rare':
  - *Immune System Disorders:* drug rash with eosinophilia and systemic symptoms (DRESS)
  - *Gastrointestinal disorders:* intestinal necrosis, intestinal ulceration and intestinal perforation, all 3 of these reactions were sometimes fatal
  - *Renal and Urinary disorders –'very rare':* specification to **tubulo**interstitial nephritis.

**The update to Zaponex PATIENT INFORMATION LEAFLET is in accordance with changes to SPC section 4.8.**

The most important changes in the PIL are in **Section 4: possible side effects**, which has listed additional side effects from post marketing experience (section 'Not known') for the organ system categories Immune System Disorders and Gastrointestinal Disorders, as above.